Latest News

Sienna IPO Closing July 17th 11-Jul-2017

Sienna’s Initial Public Offering (IPO) to raise up to $6M through the issuance of up to 30 mil.. READ MORE

Sienna Seeks Listing on ASX with IPO 08-Jun-2017

Sienna has applied to the ASX for listing on the Australian Stock Exchange. The company plan.. READ MORE

Resources Added to Drive Key Strategies 04-May-2017

Sienna has added two key resources to the business to enable planning and execution of key strategie.. READ MORE

Investor Information

Sienna is a public unlisted company headquartered in Melbourne, Australia. In January 2015, Sienna transitioned from a purely Research and Development company to a true commercial entity with product revenues. The company has approximately 160 shareholders and is governed by an experienced board and management team, Sienna has benefited from over $5.7M in R&D Tax Incentive refunds and government grant programs, significantly bolstering investor contributions and facilitating the progress and growth to date. READ MORE

About Sienna

Sienna is a medical technology company focussed on the development and commercialisation of novel IVD (in vitro diagnostic) tests. Sienna manufactures IVD products for pathology laboratories to use in their menu of testing services. Sienna has IVD product registration for their Anti-hTERT Antibody (SCD-A7) in several key markets including the USA, European Union and Australia. READ MORE

Sienna has launched the first ever IVD for detection of telomerase as an adjunct to urine cytology for assisting the diagnosis of bladder cancer.

– CEO, Matthew Hoskin

Sign up to our newsletter

Contact Sienna

Sienna Cancer Diagnostics

1 Dalmore Drive Scoresby VIC 3179 Australia

Telephone +61 3 8288 2141 Facsimile +61 3 8288 2059